Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurodevelopmental and Psychiatric Disorder Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for DISC1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | DISC1 Recombinant Protein / Specific Domain Truncations High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View DISC1 Products |
| Gene Delivery | DISC1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and primary neuron transduction. |
View DISC1 Products |
| Benchmark Ab | Anti-DISC1 Recombinant Antibody Recombinant positive control for Western Blot, IHC, and IP validation. |
View DISC1 Products |
| Validator | DISC1 siRNA Set For knockdown verification in neural progenitor cells. |
View DISC1 Products |
| Related Target A | PDE4D Interacts directly with DISC1; key regulator of cAMP signaling in psychiatric pathophysiology. |
View PDE4D Products |
| Related Target B | NDE1 Essential partner in the DISC1-dynein complex regulating neurogenesis and neuronal migration. |
View NDE1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular Protein-Protein Interaction (PPI) Screening | High-purity recombinant DISC1 and PDE4D/NDE1 partner proteins with verified theoretical MW and sequence accuracy. |
| Modeling in Primary Neurons / iPSCs | High-titer, endotoxin-controlled Lentivirus Premade Particles for stable, long-term expression without toxicity. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and high-affinity positive controls included. |
| False Positives in Knockdown Studies | Chemically synthesized siRNA pools validated for sequence specificity to ensure clean phenotypic readouts. |
Live DISC1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for DISC1 therapeutics is intensifying, with major players shifting focus from traditional global gene knockouts to targeted small-molecule disruptors of protein-protein interactions (PPI) and gene therapy vectors. As first-generation psychiatric therapies reach clinical limits, the next wave of R&D is targeting specific intracellular protein complexes to restore synaptic plasticity and cognitive function.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitors) | Academic Consortia, Specialty Neuro-Pharma | Schizophrenia, Major Depressive Disorder (MDD) | In vitro binding assays (Need high-purity DISC1-PDE4D complex proteins) |
| Gene Therapy (AAV/Lentivirus) | Biotech Startups, Gene Therapy Pioneers | Neurodevelopmental Disorders, Cognitive Deficits | Transduction efficiency validation (Need high-titer Lentivirus controls) |
| Peptide Therapeutics | Translational Medicine Centers | Bipolar Disorder, Synaptic Dysfunction | Efficacy validation in neural stem cells (Need validated siRNA and functional proteins) |